Product Profiles

Article

A round up of new products

Preservative-free eye drop

Santen is a Japanese R&D focused pharmaceutical company specializing in the development and manufacturing of ophthalmic products.

Learn more about this and Santen's other offerings at http://www.santen.eu/

Cornea marking for toric IOLs

Tomark enables the practitioner to adjust the angle with an accuracy of 5° permitting exact staining of the calculated cylinder axis. The marking is performed while the patient is in the upright position so that faulty markings as a result of cyclotorsion are prevented. Additionally, the adjustable instrument can either be used on a slit lamp or in combination with a handheld pendulum instrument, both of which guarantee excellent marking conditions.

The procedure takes a few seconds because minimal pressure is required for sufficient staining and as a result of its ease-of-use and reliability, corneal marking may also be performed by assisting personnel.

If you would like further information please contact info@geuder.de

Continuous measurement of IOP

Additionally, the Sensor features a telemetric chip and a micro loop antenna for wireless reception of power and return of data. The patient wears the system for 24 hours, assuming normal activities inlcuding sleep, while the flexible adhesive Antenna that is worn around the eye and connected to a portable Recorder through a thin flexible Data cable monitors IOP. All the data from the Recorder is then transferred via Bluetooth wireless connection to the practioner's computer.

Information provided by the Sensimed Triggerfish enables a patient's treatment to be personalized and aids with the diagnosis and management of glaucoma. This system is available in many European countries.

For more information visit http://www.sensimed.ch/

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.